The drug manufacturer said its investors would receive 62.5 pence per share under the deal, a 40.9 per cent premium to its closing share price on Thursday.Read More

You might also be interested in reading Deep Dive on Hedera – It’s quietly becoming one of the go-to chains for institutions.